Sonnet BioTherapeutics (SONN) Institutional Ownership → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free SONN Stock Alerts $1.80 +0.01 (+0.56%) (As of 05/16/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Sonnet BioTherapeutics (NASDAQ:SONN)CurrentInstitutional OwnershipPercentage9.45%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$14.87MNumber ofInstitutional Sellers(last 12 months)0 Get SONN Insider Trade Alerts Want to know when executives and insiders are buying or selling Sonnet BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SONN Institutional Buying and Selling by Quarter Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Sonnet BioTherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/27/2023Virtu Financial LLC86,624$42K0.0%N/A0.315% 5/19/2023 Anson Funds Management LP1,760,000$634K0.1%N/A6.405% 11/7/2022Virtu Financial LLC26,914$40K0.0%N/A0.622% 8/2/2022 Advisory Services Network LLC130,525$37K0.0%+158.3%0.215% 5/10/2022 Campion Asset Management90,612$34K0.0%N/A0.150% 8/16/2021 State Street Corp62,688$99K0.0%N/A0.253% 8/13/2021 Vanguard Group Inc.701,634$1.11M0.0%+416.0%2.834% 5/19/2021Virtu Financial LLC65,106$146K0.0%N/A0.371% 5/18/2021 Citadel Advisors LLC113,264$255K0.0%N/A0.534% 5/18/2021Jane Street Group LLC17,304$39K0.0%N/A0.099% 5/17/2021 Price T Rowe Associates Inc. MD45,100$101K0.0%N/A0.257% 5/13/2021 Bank of New York Mellon Corp20,399$46K0.0%N/A0.116% 5/7/2021 BlackRock Inc.255,761$575K0.0%+3.7%1.457% 3/26/2021Susquehanna International Group LLP15,434$34K0.0%N/A0.088% 2/9/2021 Advisory Services Network LLC24,581$55K0.0%+32.3%0.143% 2/5/2021 BlackRock Inc.246,555$550K0.0%+2.5%1.435% 11/19/2020 Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.071% 11/19/2020 IHT Wealth Management LLC10,000$26K0.0%N/A0.058% 11/17/2020 Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.089% (Data available from 1/1/2016 forward) SONN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SONN shares? During the previous two years, the following institutional investors and hedge funds held shares of Sonnet BioTherapeutics shares: Anson Funds Management LP ($634K), and Virtu Financial LLC ($42K), Advisory Services Network LLC ($37K).Learn more on SONN's institutional investors. What percentage of Sonnet BioTherapeutics stock is owned by institutional investors? 9.45% of Sonnet BioTherapeutics stock is owned by institutional investors. Learn more on SONN's institutional investor holdings. Which institutional investors have been buying Sonnet BioTherapeutics stock? The following institutional investors have purchased Sonnet BioTherapeutics stock in the last 24 months: Anson Funds Management LP ($1.76M), Virtu Financial LLC ($113.54K), and Advisory Services Network LLC ($80K). How much institutional buying is happening at Sonnet BioTherapeutics? Institutional investors have bought a total of 1,953,538 shares in the last 24 months. This purchase volume represents approximately $22.64M in transactions. Related Companies: TFF Pharmaceuticals Institutional Ownership Cingulate Institutional Ownership Genprex Institutional Ownership NexImmune Institutional Ownership Seelos Therapeutics Institutional Ownership ZyVersa Therapeutics Institutional Ownership Kazia Therapeutics Institutional Ownership Adial Pharmaceuticals Institutional Ownership Petros Pharmaceuticals Institutional Ownership Lixte Biotechnology Institutional Ownership This page (NASDAQ:SONN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.